Global Antibiotic R&D Partnership (GARDP)’s Post

Public understanding of how Antimicrobial Resistance (AMR) works, and how it can be avoided, is critical in the global fight against #AMR. Increasing misconceptions about AMR highlights the urgent need for better communication and education, not only about AMR but also about other biological processes that occur in our own bodies daily. #GlobalHealth #OneHealth #AMR #AntimicrobialResistance

The rise of bacteriophage therapy as an alternative to antibiotics is one trend in microbiology that grabbed my attention without permission😎 When microorganisms evolve to resist antibiotics, antimicrobial resistance (AMR) occurs, threatening decades of medical progress. AMR leads to longer hospital stays, higher costs, and increased mortality, making it a critical issue. Bacteriophage therapy uses bacteriophages: viruses that target and kill specific bacteria, to treat infections that no longer respond to conventional antibiotics. What excites me about this therapy is its precision: it targets harmful bacteria without affecting beneficial microbes or human cells, offering a safer treatment option. You may wonder why phages aren’t as widely used as antibiotics. One major reason is their narrow host range. Unlike antibiotics that can kill a wide range of bacterial species, phages typically only infect and kill one specific type of bacteria. I’m eager to see how bacteriophage therapy, alongside ongoing AMR research, will shape the future of microbiology and contribute to new treatment solutions. #MicrobiologyAndFoodScience #IndustryTrends #Day8of25 #BacteriophageTherapy #AMR

#𝗣𝗮𝘁𝗵𝗼𝗯𝗹𝗼𝗰𝗸𝗲𝗿𝘀, 𝗮 𝗳𝘂𝘁𝘂𝗿𝗲 𝗮𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲 𝘁𝗼 #𝗮𝗻𝘁𝗶𝗯𝗶𝗼𝘁𝗶𝗰𝘀? In most cases, antibiotics are a reliable form of protection against bacterial infections. They have saved billions of human lives since their introduction. This protection, however, is threatened by bacteria’s resistance to classical antibiotics and by their aggressive pathogenicity. Currently, one in seven bacterial pneumonia patients in Germany dies while hospitalized – despite the use of antibiotics. This amounts to about 30,000 people per year. The cause of death in these cases is often toxins released by the bacteria, which attack and ultimately destroy the cells of the infected person. Antibiotics do not protect against these bacterial toxins. A study published in Nature Communications now raises hopes for new treatment options. 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿𝘀 “𝗱𝗲𝗳𝗮𝗻𝗴𝗶𝗻𝗴” 𝗯𝗮𝗰𝘁𝗲𝗿𝗶𝗮, 𝗿𝗲𝗻𝗱𝗲𝗿𝗶𝗻𝗴 𝘁𝗵𝗲𝗺 𝗵𝗮𝗿𝗺𝗹𝗲𝘀𝘀: https://lnkd.in/etVuS5Bg Freie Universität Berlin, Charité - Universitätsmedizin Berlin, Jörg Rademann, Umer Aziz, Ali Saoud, Marcel Bermudez, Amira Atef, Christoph Arkona, Gerhard Wolber

Used for treating bacterial infections, antibiotics are an essential part of modern medicine. However, this crucial treatment option is in jeopardy. Antibiotic resistance – where bacteria become resistant to antibiotics – led to more than 1 million deaths worldwide in 2019. At the University of Basel in Switzerland, Professor Christoph Dehio leads the NCCR AntiResist which is applying new research methods to speed up the discovery and development of new #antibiotics and complementary anti-infective strategies, thereby helping to reduce the problem of #antibioticresistance. https://lnkd.in/efHV29Er

The fight against antibiotic resistance is a global effort, with researchers and organizations worldwide collaborating to share knowledge, resources, and strategies. This collective approach aims to stay ahead of the evolving threat of antibiotic-resistant bacteria. The article highlights the multifaceted and collaborative efforts being made to address one of the most pressing challenges in modern medicine.

📢𝐖𝐞 𝐜𝐚𝐧 𝒂𝒃𝒔𝒐𝒍𝒖𝒕𝒆𝒍𝒚 𝐝𝐨 𝐛𝐞𝐭𝐭𝐞𝐫 𝐢𝐧 𝐚𝐧𝐭𝐢𝐛𝐢𝐨𝐭𝐢𝐜 𝐩𝐫𝐞𝐬𝐜𝐫𝐢𝐛𝐢𝐧𝐠 𝐟𝐨𝐫 𝐜𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲-𝐨𝐧𝐬𝐞𝐭 𝐬𝐞𝐩𝐬𝐢𝐬 📢 New research highlight from my weekly literature review! I'm excited to share a significant study funded by CDC, AHRQ, NIH and led by Drs. Rhee and Klompas of Harvard Dept. of Population Medicine. The study published recently in JAMA Network Open that delves into the trends in empiric broad-spectrum antibiotic use for suspected community-onset sepsis among 6,272,538 hospitalizations in U.S. hospitals. 🔍 Key Findings: ▪ Increasing Use: From 2017 to 2021, the use of empiric anti-MRSA or antipseudomonal β-lactam therapy for suspected community-onset sepsis increased from 63.0% to 66.7%. ▪ Low Resistance: Despite this rise, resistant organisms were isolated in less than 10% of patients treated with these broad-spectrum agents. Specifically, only 7.3% of cases had resistant pathogens. ▪ Unnecessary Use: Alarmingly, the study found that a substantial proportion of these antibiotic courses were likely unnecessary in retrospect, as most treated patients had no resistant organisms detected. 𝐓𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐮𝐧𝐝𝐞𝐫𝐬𝐜𝐨𝐫𝐞𝐬 𝐭𝐡𝐞 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐧𝐞𝐞𝐝 𝐟𝐨𝐫 𝐜𝐨𝐧𝐭𝐢𝐧𝐮𝐞𝐝 𝐯𝐢𝐠𝐢𝐥𝐚𝐧𝐜𝐞 𝐚𝐧𝐝 𝐨𝐩𝐭𝐢𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐚𝐧𝐭𝐢𝐦𝐢𝐜𝐫𝐨𝐛𝐢𝐚𝐥 𝐬𝐭𝐞𝐰𝐚𝐫𝐝𝐬𝐡𝐢𝐩 𝐩𝐫𝐚𝐜𝐭𝐢𝐜𝐞𝐬, 𝐩𝐚𝐫𝐭𝐢𝐜𝐮𝐥𝐚𝐫𝐥𝐲 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐧𝐭𝐞𝐱𝐭 𝐨𝐟 𝐜𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲-𝐨𝐧𝐬𝐞𝐭 𝐬𝐞𝐩𝐬𝐢𝐬. 📊 Visual Insights: Check out the trends over the years, highlighting the discrepancy between antibiotic use and the actual isolation of resistant pathogens. 🔗 https://lnkd.in/gqrhDJJi #InfectiousDiseases #AntimicrobialStewardship #Sepsis #HealthcareResearch #PublicHealth

"visual insights: check out the trends over the years, highlighting the discrepancy between antibiotic use and the actual isolation of resistant pathogens":

‼ How Triclosan in Your Soap Could Make Bacteria More Dangerous❗️ ❗ Recent research has uncovered a surprising downside to using #triclosan, a common disinfectant found in many household products like soaps and toothpaste. 💡 Scientists discovered that exposing bacteria to triclosan can make them not only resistant to this disinfectant but also to antibiotics used in medical treatments. Even more concerning, the bacteria become more capable of acquiring resistance genes from other bacteria, making them harder to treat with standard medications. On the flip side, these triclosan-resistant bacteria become more vulnerable to attacks by certain viruses (phages) that can kill them, suggesting a potential new way to fight these superbugs. 🔴 This study highlights the complex effects of everyday chemicals on bacterial behavior and the ongoing battle against antibiotic resistance. 🔴 EXPLORE : https://lnkd.in/d8yqsPSu #antimicrobialresistance #onehealth #antibiotics #disinfectant #superbugs #antibioticresistance #microvioma Maneesh Paul. S., M. Sc., Ph.D., FIDSA., Qiu E. Yang, Xiaodan Ma, Minchun Li, Mengshi Zhao, Lingshuang Zeng, Minzhen He, Hui Deng, Hanpeng Liao, Christopher Rensing, Ville-Petri Friman, Shungui Zhou & Timothy R. Walsh

Tackling antimicrobial resistance: the urgent need for new antibiotics Antibiotics have revolutionized modern medicine, but antimicrobial resistance (AMR) is making once-easily treatable infections harder to cure and more dangerous. The lack of investment in new antibiotics since the 1980s is a growing concern. With drug-resistant infections projected to claim millions of lives by 2050, urgent action is needed. The development of new antibiotics, including combination therapies, shows promise, but sustained global investment is essential to combat AMR. The future of public health depends on innovative solutions and global collaboration. Read more: https://buff.ly/41NynAM @HealthZA @SAMAnew @SA_Medical_Research @WHO @AMR_Africa @SAAMS_org @IAPAC #AntimicrobialResistance #AMR #Antibiotics #PublicHealth #InfectiousDiseases #GlobalHealth

Antimicrobials have drastically changed modern medicine and extended the average human lifespan by 23 years. However, over the past 30 years there has been a gradual decline in antibiotic R&D with rising levels of antimicrobial resistance (AMR) posing a significant global threat to human health. In 2019, the World Health Organisation (WHO) estimated that AMR was linked to around five million deaths and if this trend continues, annual AMR-related deaths could reach 10 million by 2050, with an estimated cost of $100 trillion to the global economy. Although 16 new antibiotics have been approved since 2017, many pathogens still have no treatments as most new antibiotics are associations or improvements of existing molecules, originally discovered over 30 years ago. There is therefore an urgent need for more innovative mechanisms of action and new chemical classes of antimicrobials. This blog explores recent developments in incentivising antibiotic R&D, the current R&D pipeline and the potential of GenAI in identifying new therapies and reducing the risk of AMR.